Facebook
Twitter
LinkedIn
Forward
A New Wave of Topical Therapies for Atopic Dermatitis: Comparing Treatment Approaches
Topical therapies are considered the mainstay treatment for atopic dermatitis (AD). However, traditional topicals such as corticosteroids and calcineurin inhibitors are associated with limitations for use and safety concerns. In addition, treatment guidelines for AD provide few to no recommendations for selecting therapies and, as a result, treatment selection for each patient can be complex and subjective. New targeted topical therapies are becoming increasingly available, and clinicians must be familiar with the latest clinical data and how to utilize them in clinical practice. Despite treatment advances, challenges in the management of AD persist including poor topical therapy adherence and topical corticosteroid abuse.
This educational activity provides up-to-the-minute clinical data on current and emerging topical therapies for AD as well as expert strategies for treatment selection and long-term control of the disease.
Target Audience
This activity is designed for an audience of physicians, nurse practitioners, physician assistants that specialize in dermatology.
Learning Objectives
Upon completion of the educational activity, participants should be better able to:
- Critically evaluate the clinical data and mechanism associated with current and emerging topical therapies for AD.
- Identify challenges and complications in treating AD with topical therapies and how to overcome them
- Develop individualized treatment strategies for topical therapy for AD patients.
- Introduction to AD: Etiopathogenesis and Gaps in Care
- The AD Landscape: What's Here and What's Coming Soon
- Comparing Targeted Topical Therapies: A Closer Look at the Data
- Which Therapy for Which Patient?: Key Takeaways and Closing Remarks
 |  |
Peter Lio, MD | Lisa Swanson, MD
|
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associate
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until June 28, 2025. PAs should only claim credit commensurate with the extent of their participation.
Nurses
1 ANCC contact hours.
Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 1 contact hour(s) which includes 1 hour(s) of pharmacology.
Commercial Support
This activity is supported by an independent medical education grant from Dermavant Sciences, Inc.
Disclosure
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
DISCLOSURES | ||
Name | Relationship | Commercial Interest |
Peter Lio, MD
| Advisor | Alphyn Biologics, AbbVie, Almirall, Amyris, Arcutis, ASLAN, Boston Skin Science, Bristol-Myers Squibb, Burt’s Bees, Castle Biosciences, Codex Labs, Concerto Biosci, Dermavant, Eli Lilly, Galderma, Janssen, Johnson & Johnson, Kimberly Clark, LEO Pharma, Lipidor, L’Oreal, Merck, Micreos, MyOR Diagnostics, Regeneron/Sanofi Genzyme, Sibel Health, Skinfix, Sonica, Suneco Technologies, Theraplex, UCB, Unilever, Verdant Scientific, Verrica, Yobee Care |
Individual stocks and stock options | Codex Labs, Concerto Biosci, Suneco Technologies, Yobee Care, Verdant Scientific | |
Royalties or patent beneficiary | Theraplex AIM | |
Speaker | AbbVie, Arcutis, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay/L’Oreal, MyOR Diagnostics, ParentMD, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme, Verrica | |
Lisa Swanson, MD | Consultant | Abbvie, Alphyn,Arcutis, Boehringer Ingelheim, Castle, Dermavant, Galderma, Incyte, Janssen, Leo, Lilly, Novan, Pfizer, Sanofi-Regeneron, Verrica |
| Speaker | Abbvie, Almirall, Arcutis, Galderma, Incyte, Janssen, Lilly, Novartis, Pfizer, Sanofi-Regeneron, Verrica |
Dorothy Caputo, MA, BSN, RN, VP, Healthcare CE and Operations | N/A | Nothing to disclose |
Bernadette Makar, MSN, APRN-BC, NP-C (planner/reviewer) | N/A | Nothing to disclose |
Michele Bielarski, RN (planner/reviewer) | N/A | Nothing to disclose |
AKH Inc Staff and Planners | N/A | Nothing to disclose |
Tarsus dba LiVDerm Staff and Planners | ||
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.
AKH Privacy Policy (link: https://akhcme.com/akhcme/pages/privacy)
Available Credit
- 1.00 AANP
- 1.00 AAPA Category I CME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.